Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System
Authors:
Open Access
- 21 January 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , 78-86
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registryJEADV Clinical Practice, 2022
- The Use of Biologics During the COVID-19 PandemicDermatologic Clinics, 2021
- Association Between Biologics Use and Risk of Serious Infection in Patients With PsoriasisJAMA Dermatology, 2021
- Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic ArthritisArthritis Care & Research, 2021
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialThe Lancet, 2021
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trialThe Lancet, 2019
- Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRJAMA Dermatology, 2018
- Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital databasePharmacoepidemiology and Drug Safety, 2016
- Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic TherapyArchives of Dermatology, 2012
- Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticiansStatistics in Medicine, 2000